Nadvi Naveed A, Salam Noeris K, Park Joohong, Akladios Fady N, Kapoor Vimal, Collyer Charles A, Gorrell Mark D, Church William Bret
Group in Biomolecular Structure and Informatics, Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia.
Molecular Hepatology, Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Protein Sci. 2017 Apr;26(4):727-736. doi: 10.1002/pro.3119. Epub 2017 Mar 6.
In this study, we report two high-resolution structures of the pyridoxal 5' phosphate (PLP)-dependent enzyme kynurenine aminotransferase-I (KAT-I). One is the native structure with the cofactor in the PLP form bound to Lys247 with the highest resolution yet available for KAT-I at 1.28 Å resolution, and the other with the general PLP-dependent aminotransferase inhibitor, aminooxyacetate (AOAA) covalently bound to the cofactor at 1.54 Å. Only small conformational differences are observed in the vicinity of the aldimine (oxime) linkage with which the PLP forms the Schiff base with Lys247 in the 1.28 Å resolution native structure, in comparison to other native PLP-bound structures. We also report the inhibition of KAT-1 by AOAA and aminooxy-phenylpropionic acid (AOPP), with IC50s of 13.1 and 5.7 μM, respectively. The crystal structure of the enzyme in complex with the inhibitor AOAA revealed that the cofactor is the PLP form with the external aldimine linkage. The location of this oxime with the PLP, which forms in place of the native internal aldimine linkage of PLP of the native KAT-I, is away from the position of the native internal aldimine, with the free Lys247 substantially retaining the orientation of the native structure. Tyr101, at the active site, was observed in two conformations in both structures.
在本研究中,我们报道了磷酸吡哆醛(PLP)依赖性酶犬尿氨酸转氨酶-I(KAT-I)的两个高分辨率结构。一个是天然结构,其中辅因子以PLP形式与赖氨酸247结合,分辨率为1.28 Å,是目前KAT-I的最高分辨率结构;另一个是与一般PLP依赖性转氨酶抑制剂氨氧基乙酸(AOAA)共价结合辅因子的结构,分辨率为1.54 Å。与其他天然PLP结合结构相比,在1.28 Å分辨率天然结构中,PLP与赖氨酸247形成席夫碱的醛亚胺(肟)键附近仅观察到微小的构象差异。我们还报道了AOAA和氨氧基苯丙酸(AOPP)对KAT-1的抑制作用,其IC50分别为13.1和5.7 μM。酶与抑制剂AOAA复合物的晶体结构表明,辅因子为具有外部醛亚胺键的PLP形式。该肟与PLP的位置取代了天然KAT-I中PLP的天然内部醛亚胺键,远离天然内部醛亚胺的位置,游离的赖氨酸247基本保持天然结构的取向。在两个结构中,活性位点的酪氨酸101均观察到两种构象。